09:21 AM EDT, 09/08/2025 (MT Newswires) -- Microbot Medical ( MBOT ) said Monday that the US Food and Drug Administration has granted 510(k) clearance for its Liberty endovascular robotic system.

The company said the issuance of the marketing clearance allows it to begin commercialization in Q4 in the US, where about 2.5 million peripheral vascular procedures are conducted yearly.

Microbot said it plans to continue its clinical data collection for the device during the commercial launch.

Shares of the company were up more than 8% in recent premarket activity Monday.